Search

Search Results

• 

  Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature

  Pablo Santa María, Fernando Valenzuela, Claudia Morales, Raul De la Fuente, Roberto Cullen

  11-10-2017

  https://doi.org/10.4081/dr.2017.7079

  1434

  PDF: 683

  HTML: 147

• Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

  Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  12-11-2024

  https://doi.org/10.4081/dr.2024.10080

  1352

  PDF: 736

  HTML: 42
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1160

  PDF: 573

  HTML: 25

• 26 | CONCOMITANT THERAPY WITH IXEKIZUMAB PLUS TIRZEPATIDE IN ADULTS WITH PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY DEMONSTRATED SUPERIOR DISEASE CONTROL COMPARED TO IXEKIZUMAB ALONE: RESULTS FROM THE PH3B TOGETHER-PSA TRIAL E. Filippi¹, J. F. Merola², P. Mease³, A. Kivitz⁴, N. Sattar⁵, L. C. Coates⁶, C. E. Kartman⁷, P. Fischer⁷, L. Sun⁷, A. Cardoso⁷, M. C. Genovese⁷, A. Ogdie⁸ | ¹Eli Lilly Italia S.p.A, Florence, Italy; ²Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; ³Providence Swedish Medical Center, Seattle, WA, USA; ⁴Altoona Center for Clinical Research, Duncansville, PA, USA; ⁵School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; ⁷Eli Lilly and Company, Indianapolis, IN, USA; ⁸Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

  Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica

  24-09-2026

  https://doi.org/10.4081/dr.2026.11088

  0

  PDF: 0

• 25 | EARLY AND MAINTAINED TREAT-TO-TARGET RESPONSE WITH IXEKIZUMAB UP TO 5 YEARS IN MODERATE-TO-SEVERE PSORIASIS: A POST-HOC ANALYSIS OF UNCOVER-3 E. Filippi¹, A. Armstrong², J. F. Merola³, M. Megna⁴, X. Man⁵, M. Honma⁶, J-M. Carrascosa⁷, R. Chughtai⁷, K. Fotiou⁸, S. Sabatino⁸, M. Ngantcha⁸, A. Pinter⁹ | ¹Eli Lilly Italia S.p.A, Florence, Italy; ²University of California, Los Angeles, CA, USA; ³University of Texas Southwestern Medical Center, Dallas, TX, USA; ⁴University of Naples Federico II, Naples, Italy; ⁵Zhejiang University, Hangzhou, China; ⁶Asahikawa Medical University, Asahikawa, Japan; ⁷Hospital Germans Trias, Universitat Autònoma de Barcelona, Barcelona, Spain; ⁸Eli Lilly and Company, Indianapolis, IN, USA; ⁹University Hospital Frankfurt, Frankfurt, Germany

  Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica

  24-09-2026

  https://doi.org/10.4081/dr.2026.11087

  0

  PDF: 0
• 

  Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

  Martina Vispi, Teresa Corradin, Camilla Peccianti, Luca Feci, Laura Casini, Chiara Pisani, Susanna Fabbroni, Paola Corsetti, Margherita Croatto, Michele Pellegrino

  25-06-2020

  https://doi.org/10.4081/dr.2020.8642

  1407

  PDF: 771

  HTML: 17

• 24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL E. Filippi¹, M. Lebwohl², A. Blauvelt³, C. Kartman⁴, C. Leatherwood⁴, K. Gordon⁵, N. Sattar⁶, L. Puig⁷, J. Merola⁸, K. Siu⁴, R. Wang⁴, L. Sun⁴, A. Leung⁹, N. Somani⁴, M. Rueda⁴, A. Cardoso⁴, M. Genovese⁴, A. Armstrong¹⁰, B. Strober¹¹ | ¹Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy; ²Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ³Blauvelt Consulting, LLC, Annapolis, MD, USA; ⁴Eli Lilly and Company, Indianapolis, IN, USA; ⁵Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁶School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; ⁷Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain; ⁸Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; ⁹Syneos Health, Morrisville, NC, USA; ¹⁰Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA; ¹¹Department of Dermatology, Yale University School of Medicine, New Haven, CT, Central Connecticut Dermatology Research, Cromwell, CT, USA

  Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica

  24-09-2026

  https://doi.org/10.4081/dr.2026.11086

  0

  PDF: 0

• Pityriasis following COVID-19 vaccinations: a systematic review

  Laura Duzett, Guadalupe Mercado, Vasiliki Tasouli-Drakou, Alicia Kane, Alison Tam

  09-08-2023

  https://doi.org/10.4081/dr.2023.9742

  1380

  PDF: 774

  Supplementary Material: 156

  HTML: 85
• 

  Certolizumab to treat hidradenitis suppurativa

  Asem Shadid, Saud Alobaida, Yousef Binamer

  27-10-2022

  https://doi.org/10.4081/dr.2022.9566

  1979

  PDF: 753

  HTML: 53

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  1076

  PDF: 570

  SUPPLEMENTARY MATERIAL: 184

  HTML: 21

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  498

  PDF: 319

  HTML: 23
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1210

  PDF: 859

  HTML: 47

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  562

  PDF: 381

  HTML: 11